US-based healthcare diagnostic technology provider Cue Health has secured more than $45m in its series B round, from a consortium including corporate venturing units Johnson & Johnson Innovation – JJDC and Dentsu Ventures.
The units, subsidiaries of medical product group Johnson & Johnson and marketing firm Dentsu, were joined by Section 32, Synergy Ventures, Principles of Tarsadia Investments, Pritzker Group Venture Capital, Babel Ventures, Troy Capital, Sherpa Capital, Cove Investments and private investor Rohan Oza.
Cue is developing personal diagnostics…
